Balchem Reports Third Quarter 2025 Financial Results

Montvale, NJ, October 21, 2025 – Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2025 fiscal third quarter ended September 30, 2025. For the quarter, the Company reported net sales of $267.6 million, net earnings of $40.3 million, adjusted EBITDA(a) of $71.4 million, and free cash flow(a) of $50.7 million.

Ted Harris, Chairman, President and CEO of Balchem said, “In the third quarter, our company continued to deliver strong growth, fueled by the ongoing market penetration of our unique portfolio of specialty nutrients and delivery systems, and the favorable ‘better for you’ trends within the food and nutrition markets that are well aligned with our food ingredient formulation systems and capabilities.”

Third Quarter 2025 Financial Highlights:

• Record net sales of $267.6 million, an increase of $27.6 million, or 5%, compared to the prior year quarter.
• GAAP net earnings were $40.3 million, an increase of 1%, from the prior year quarter.
• Record adjusted EBITDA was $71.4 million, an increase of 0%, from the prior year quarter.
• GAAP earnings per share of $1.24 compared to $1.03 in the prior year quarter and record adjusted earnings per share(a) of $1.35 compared to $1.13 in the prior year quarter.
• Cash flows from operations were $65.6 million, with free cash flow(a) of $50.7 million.
• Sales and earnings from operations growth in all three of our reporting segments.

Recent Highlights:

• Balchem has received the necessary approvals to move forward with the project to build its new state-of-the-art food ingredient and nutraceutical microencapsulation manufacturing facility in Orange County, NY, which will more than double capacity for its fast-growing microencapsulation technologies.
• We have seen good results year to date from our sponsored research efforts with five new studies being published in the third quarter, one of which being the long awaited choline “biomarker” study, a double-blind randomized control feeding study at the University of North Carolina that successfully identified that choline and betaine concentrations in plasma, when measured together, do indeed predict dietary choline intake in healthy humans.
• Strong cash flows in the third quarter enabled us to make net repayments on our revolving debt of $36.0 million, bringing our net debt (b) to $88.9 million, with an overall leverage ratio (c) on a net debt basis of 3 times.

See “Non-GAAP Financial Information” for reconciliations of GAAP and non-GAAP financial measures.

Quarterly Conference Call

A quarterly conference call will be held on Tuesday, October 21, 2025, at 11:00 AM Eastern Time (ET) to review third quarter 2025 results. Ted Harris, Chairman, President and CEO and Martin Bengtsson, CFO will host the call. Institutional investors and analysts are invited to join the live call by dialing 800-715-9871 (toll free USA/Canada), +1-646-307-1963 (USA/International) or 647-932-3411 (Canada/Toronto), five minutes prior to the scheduled start time of the conference call. All others are invited to listen to the live webcast at https://events.q4inc.com/attendee/857727932. The conference call will be available for replay shortly after the conclusion of the call at https://events.q4inc.com/attendee/857727932 for one year.